AUS
NZ
UK
CA
USA
IND
Healthcare
Osteopore Malaysia Approval Gains ASX 300 Focus
May 15, 2026 09:57 AM AEST| By SamOsteopore strengthened healthcare technology visibility following orthopaedic approval developments linked to regional healthcare expansion activity in Malaysia.
Why This ASX Biotech Name Is Drawing Fresh Market Attention
May 15, 2026 09:35 AM AEST| By SamImugene attracted renewed market attention as investors focused on oncology innovation, advanced cell therapy development, and the broader transformation underway across global healthcare and precision medicine infrastructure.
Tax-Free Edge Driving Attention Towards Acrux Shares
May 14, 2026 05:54 PM AEST| By SamAcrux shareholders remain shielded from Australia’s latest capital gains tax overhaul, strengthening attention on tax-efficient investment structures and the evolving landscape of Australian equities.
Breathes New Life Into Anxiety Care With Clinical Progress
May 14, 2026 03:50 PM AEST| By SamNexalis Therapeutics advances inhaled CBD research after completing an important clinical study milestone, highlighting innovation in mental health treatment and biotechnology development.
Why CSL’s Recovery Story Is Turning Heads on the ASX Stocks
May 14, 2026 03:23 PM AEST| By SamCSL is showing signs of operational recovery as plasma collections improve, vaccine demand remains resilient, and healthcare trends continue supporting long-term growth across specialised global markets.
ASX 200 Healthcare Stock Watch: TLX In Focus
May 14, 2026 12:53 PM AEST| By SamASX biotechnology and healthcare sector remained in focus as TLX continued attracting attention through radiopharmaceutical activity and healthcare innovation developments.
ASX 20 Healthcare Sector Update: CSL Shares And Market Activity
May 14, 2026 10:59 AM AEST| By SamAustralia’s healthcare sector remained active as CSL continued drawing attention through biotechnology operations, plasma services, and pharmaceutical market participation.
Why These ASX Healthcare Shares Are Riding Australia’s Ageing Boom
May 14, 2026 10:31 AM AEST| By SamAustralia’s ageing population continued driving attention toward healthcare and aged care companies as demand for residential care, rehabilitation and hospital services strengthened across the sector.
Why This ASX Biotech Share Is Suddenly Back on the Radar
May 14, 2026 10:08 AM AEST| By SamEBR Systems returned to market focus after commercial growth, expanding hospital contracts and manufacturing developments strengthened attention on the emerging healthcare technology company despite ongoing funding concerns.
Breakthrough ALS Study Pushes Neurizon Into Spotlight
May 13, 2026 07:36 PM AEST| By SamNeurizon Therapeutics advances its ALS research program with ethics approval for an oral liquid study, supporting treatment accessibility and strengthening its broader clinical development strategy.
Healthcare Jitters Deepen After Healius and CSL Shock
May 13, 2026 05:29 PM AEST| By SamHealthcare stocks on the ASX remain under pressure as Healius and CSL trigger renewed concerns around margins, labour costs, funding support and sector-wide earnings stability.
Anteris Expands US Trial Push Amid Heart Valve Focus
May 13, 2026 04:31 PM AEST| By SamAnteris Technologies Global advances its US heart valve trial strategy with fresh funding, manufacturing expansion, and regulatory momentum as clinical development activities continue to strengthen.
ASX Healthcare Stock Expands Capital Base With New Shares
May 13, 2026 11:23 AM AEST| By SamActinogen Medical expanded its quoted share base after issuing additional ordinary shares through option and convertible security exercises.
Amplia Therapeutics Expands Market Presence on ASX Stocks
May 12, 2026 05:30 PM AEST| By SamAmplia Therapeutics expanded its ASX-listed share base, reinforcing biotechnology sector momentum and highlighting continued healthcare innovation activity across Australia’s evolving equity market landscape.
Bioxyne Broadens European Presence Through German Supply Pact
May 12, 2026 02:51 PM AEST| By SamBioxyne broadens its European medicinal cannabis footprint through a major German supply agreement, supporting long-term expansion, stronger revenue visibility, and growing international market access.
CSL Shock Sends ASX Healthcare Sector Into Sharp Retreat
May 12, 2026 01:40 PM AEST| By SamCSL’s sharp decline weighed heavily on the healthcare sector while rising commodity prices supported mining and energy stocks across the australian stock market.
Why Mesoblast Could Be the ASX Biotech Stock Back in Focus
May 12, 2026 11:10 AM AEST| By SamMesoblast remains in focus as healthcare investors watch commercial progress, therapy expansion, and broader biotech sector recovery trends across the australian stock market.
Why Mesoblast Is Back in Focus Among ASX Biotech Stocks
May 12, 2026 10:02 AM AEST| By SamMesoblast is regaining investor attention as commercial progress, pipeline diversification, and broader healthcare innovation themes continue supporting interest in ASX biotech stocks.
Why 4DMedical’s CT:VQ Expansion Is Drawing Fresh ASX Attention
May 12, 2026 09:43 AM AEST| By Sam4DMedical is gaining stronger market attention as CT:VQ expansion, international regulatory progress, and ASX 200 inclusion reshape its healthcare technology growth narrative.
CSL Faces Fresh Pressure After Major Impairment Update
May 11, 2026 06:00 PM AEST| By SamCSL updates market outlook with impairment expectations, healthcare segment pressures, and operational changes as investors assess the future direction of the Australian biotech giant.
Advertise your brand on Kalkine Media